BGI Genomics Co Ltd (300676) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-3.08 Million ≈ $-451.41K USD) by net assets (CN¥9.37 Billion ≈ $1.37 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300676 stock market capitalisation for the company's overall valuation and market capitalisation.
BGI Genomics Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how BGI Genomics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BGI Genomics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BGI Genomics Co Ltd ranked by their cash flow conversion efficiency. Explore 300676 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dialog Group Bhd
KLSE:7277
|
0.096x |
|
JOYY Inc
NASDAQ:JOYY
|
0.005x |
|
Plug Power Inc
NASDAQ:PLUG
|
-0.160x |
|
Resideo Technologies Inc
NYSE:REZI
|
-0.050x |
|
Sichuan Qiaoyuan Gas Co.Ltd
SHE:301286
|
0.004x |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
0.052x |
|
Steadfast Group Limited
F:1S6
|
0.055x |
|
Transmissora Aliança de Energia Elétrica S.A
SA:TAEE11
|
0.086x |
Annual Cash Flow Conversion Efficiency for BGI Genomics Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of BGI Genomics Co Ltd from 2012 to 2025. View BGI Genomics Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.61 Billion ≈ $1.26 Billion |
CN¥-63.21 Million ≈ $-9.25 Million |
-0.007x | -171.13% |
| 2024-12-31 | CN¥9.27 Billion ≈ $1.36 Billion |
CN¥95.72 Million ≈ $14.01 Million |
0.010x | -74.73% |
| 2023-12-31 | CN¥10.00 Billion ≈ $1.46 Billion |
CN¥408.77 Million ≈ $59.82 Million |
0.041x | +219.10% |
| 2022-12-31 | CN¥10.22 Billion ≈ $1.50 Billion |
CN¥130.88 Million ≈ $19.15 Million |
0.013x | -95.12% |
| 2021-12-31 | CN¥9.44 Billion ≈ $1.38 Billion |
CN¥2.48 Billion ≈ $362.34 Million |
0.262x | -56.13% |
| 2020-12-31 | CN¥6.03 Billion ≈ $881.76 Million |
CN¥3.60 Billion ≈ $527.19 Million |
0.598x | +1088.56% |
| 2019-12-31 | CN¥4.46 Billion ≈ $652.35 Million |
CN¥224.25 Million ≈ $32.82 Million |
0.050x | +1315.25% |
| 2018-12-31 | CN¥4.13 Billion ≈ $604.67 Million |
CN¥14.69 Million ≈ $2.15 Million |
0.004x | -93.79% |
| 2017-12-31 | CN¥4.26 Billion ≈ $623.07 Million |
CN¥243.66 Million ≈ $35.66 Million |
0.057x | -15.59% |
| 2016-12-31 | CN¥3.45 Billion ≈ $505.22 Million |
CN¥234.07 Million ≈ $34.25 Million |
0.068x | -34.62% |
| 2015-12-31 | CN¥3.17 Billion ≈ $463.80 Million |
CN¥328.68 Million ≈ $48.10 Million |
0.104x | +1961.44% |
| 2014-12-31 | CN¥1.47 Billion ≈ $214.45 Million |
CN¥-8.16 Million ≈ $-1.19 Million |
-0.006x | -109.08% |
| 2013-12-31 | CN¥597.94 Million ≈ $87.50 Million |
CN¥36.70 Million ≈ $5.37 Million |
0.061x | -87.27% |
| 2012-12-31 | CN¥150.37 Million ≈ $22.00 Million |
CN¥72.49 Million ≈ $10.61 Million |
0.482x | -- |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more